Alan I. Edrick
Thank you, Ajay. Now I'll review in greater detail the financial results for fiscal '25 Q4 and then discuss our fiscal '26 guidance, as Ajay mentioned. Our Q4 revenues were up 5% compared to the fourth quarter of the prior fiscal year. This growth was fueled by our security division and strong execution in our Opto division partially offset by a decline in health care. Security division revenues in Q4 were $367 million, an increase of 7% year-over-year. This growth was driven by higher service revenues, robust sales of aviation and checkpoint products and contributions from the RF detection business we acquired in Q1. As expected and consistent with last quarter's trend, revenues from our large Mexico security contracts decreased in Q4 '25 to $40 million from $145 million in Q4 of the prior fiscal year. Excluding acquisitions and excluding the Mexico contracts, securities revenues grew approximately 50% in the quarter, which underscores the healthy demand in the rest of our security portfolio. Meanwhile, our Optoelectronics and Manufacturing division had a great quarter. Third-party Opto sales increased 10% year-over-year to $95 million, which is a new Q4 record for this division. This was driven by growth in our Flex contract manufacturing business and solid performance in our core Optoelectronics operations. And then on the other hand, as Ajay mentioned, we were disappointed by the decrease in Healthcare division sales. That softness in Healthcare impacted our consolidated growth rate, but we are optimistic about improving it going forward. Turning to profitability. Our Q4 '25 gross margin was 33.3%, up 120 basis points from 32.1% in Q4 of last year. The gross margin increase was largely due to a favorable revenue mix, including higher service revenues, which carry better margins as well as improved efficiencies. Of course, our margins can fluctuate based on product/service mix, volume, supply chain costs, FX, tariffs, among other factors. Operating expenses in Q4 were well controlled. SG&A was $74.7 million, or 14.8% of sales compared to $71.7 million or 14.9% of sales in Q4 last year. We continue to work diligently across all divisions, to manage our SG&A cost structure efficiently as we grow. Research and development expenses in Q4 were $18.8 million or 3.7% of revenue, up from $15.9 million or 3.3% of revenues in the same quarter last year. This increase reflects our commitment to invest in innovation, particularly in the Security and Healthcare divisions as we remain focused on developing new market-leading products that we view as vital for our long-term success. We expect this heightened focus on R&D to continue into fiscal '26 as we advance key projects such as our computed tomography scanning technology and next- gen patient monitors. Even with these investments, we have successfully leveraged our expense structure over many years. In fact, our combined SG&A and R&D expenses as a percentage of sales have decreased annually for the past 8 years from 27.6% of sales in fiscal '17 to 21.3% of sales in fiscal '25. This underscores our ability to drive operating efficiencies while still funding growth initiatives. Now moving below the operating line. Net interest and other expense in Q4 was $7.2 million, decreasing from $8.2 million in Q4 of fiscal '24. This reduction was due to lower average debt levels during the quarter and a reduced average interest rate aided by the favorable impact of the convertible notes we issued in Q1 of fiscal '25, the proceeds of which were used in part to repay higher cost borrowings. Our effective tax rate under GAAP was 19.8% in Q4 of fiscal '25 versus 18.3% in the same quarter last year. Excluding discrete tax items, our normalized effective tax rate, which is what we used in calculating non-GAAP EPS was 21.9% this quarter compared to 21.2% in the prior year quarter. On a non-GAAP basis, our adjusted operating margin for Q4 of fiscal '25 was 15.7%, up from 14.8% in Q4 last year. By segment, the Security division's adjusted operating margin was 20.4% in Q4, improving from 18.5% a year ago, thanks to the significant increase in higher-margin service revenues we discussed. Opto's adjusted operating margin was 13.6%, slightly down from 13.9% in last year's Q4. This slight decrease was due to short-term inefficiencies as our new manufacturing facility is still ramping up. We expect Opto margins to improve as that operation scales. Lastly, the adjusted operating margin of our Healthcare division was negligible in Q4. Moving to cash flow and the balance sheet. We did see improvement in operating cash flow in Q4 compared to the prior year, but it was lower than what we had anticipated. This was largely because our largest security division customer located in Mexico pushed payments that we expected in Q4 into fiscal '26. Consequently, our accounts receivable balance increased to approximately $837 million as of June 30. The good news is that we expect a substantial cash inflow in fiscal '26 as those receivables are collected. We anticipate that the receivables from Mexico customers to decline over the course of the year which should contribute to sizable operating cash flow in fiscal '26. Additionally, recent tax legislation regarding R&D expense capitalization and accelerated depreciation on capital expenditures may provide some near-term cash savings for us, further bolstering cash flow. CapEx in Q4 of fiscal '25 was $6 million, while depreciation and amortization expense was $10.9 million. Our balance sheet remains solid. At the end of fiscal '25, our net leverage was approximately 1.8 as calculated under our credit agreement. Subsequent to fiscal year-end, we amended our credit facility to extend the maturity date to July 2030 and increased the borrowing capacity at $825 million. This expanded facility enhances our liquidity and financial flexibility, we believe this positions us well to support growth initiatives and navigate any unexpected needs. Now turning to our fiscal '26 outlook. For fiscal '26, we anticipate revenues in the range of $1.805 billion to $1.85 billion, which represents year-over-year revenue growth of 5.4% to 8%. We are also expecting non-GAAP adjusted earnings per diluted share in the range of $10.11 to $10.39, which represents 8% to 11% year-over-year growth. We note this fiscal '26 non-GAAP diluted EPS guidance excludes any impact of potential impairment, restructuring and other charges, amortization of acquired intangible assets and their associated tax effects and discrete tax and other nonrecurring items. We currently believe this guidance reflects reasonable estimates. The actual impact on the company's financial results of timing changes on the expected conversion of backlog to revenues new bookings, timing of cash collections and tariffs, among other factors, is difficult to predict and could vary significantly from the anticipated impact currently reflected in our guidance. Actual revenues and non-GAAP earnings per diluted share could also vary from the guidance indicated above due to other risks and uncertainties discussed in our SEC filings. In summary, we remain focused on growing our businesses and continuing to provide innovative products and solutions to our customers. Fiscal '25 was an outstanding year for OSI, and we are carrying that momentum forward. We expect to generate strong cash flow and have the financial strength to invest in key strategic areas that will drive long-term value. Once again, as Ajay mentioned, we thank the entire global OSI team for their dedication to supporting our customers and partners, their efforts are what make these results possible. And at this time, we'd like to open the call to questions.